Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
XPHvsETF 2ETF Comparison
Choose a second ETF to run a side-by-side ETF comparison with XPH, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
XPH performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XPH ETF 2 | -3.45%– | -1.36%– | -1.12%– | +29.22%– | +42.98%– | +9.16%– |
| Flows | XPH ETF 2 | +$12M– | +$95M– | +$88M– | +$111M– | +$48M– | +$36M– |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XPH ETF 2 | +20.33%– | +23.08%– | +19.01%– | +20.26%– |
| Max drawdown | XPH ETF 2 | -5.97%– | -17.10%– | -23.45%– | -33.10%– |
| Max drawdown duration | XPH ETF 2 | 14d– | 140d– | 322d– | 1706d– |
XPH | ETF 2 | |
Last sale 3/12/2026 at 2:29 PM | $53.50 | – |
| Previous close 03/11/2026 | $55.49 | – |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
XPH | ETF 2 | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
XPH | ETF 2 | |
|---|---|---|
| Last price | $53.50 | – |
| 1D performance | -3.59% | – |
| AuM | $313.37 M | – |
| E/R | 0.35% | – |
XPH | ETF 2 | |
|---|---|---|
| Management strategy | Passive | – |
| Provider | SPDR | – |
| Benchmark | S&P Pharmaceuticals Select Industry Index | – |
| N° of holdings | 49 | – |
| Asset class | Equities | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 19, 2006 | – |
| ESG | No | – |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Top 15 holdings
Donald Trump’s Executive Orders: ETF Bulls and Bears
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
